Related Experiment Video

Updated: May 25, 2026

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

Characterization of single nucleotide polymorphisms of cytochrome p450 in an Australian deceased sample

Jennifer L Pilgrim1, Yarimar Ruiz, Alejandro Gesteira

  • 1Victorian Institute of Forensic Medicine, Department of Forensic Medicine, Monash University, 57-83 Kavanagh Street, Southbank 3006, Victoria, Australia. jenniferp@vifm.org

Current Drug Metabolism
|February 4, 2012
PubMed

Insights

Genetic variations in drug-metabolizing enzymes like CYP450 were studied in Australian deceased individuals. No direct link was found between specific genetic profiles and cause of death, including drug toxicity.

Area of Science:

  • Pharmacogenomics
  • Forensic Toxicology
  • Genetics

Background:

  • Cytochrome P450 (CYP450) isozymes are crucial for metabolizing ~80% of common drugs.
  • Drug metabolism variability due to genetic polymorphisms can influence drug efficacy and toxicity.
  • Understanding these genetic factors is vital in forensic investigations involving drug use.

Observation:

  • A cohort of Australian deceased individuals (n=486) with varied causes of death were genotyped for CYP450 single nucleotide polymorphisms (SNPs).
  • Specific CYP450 variants, including CYP2D6 poor metabolizers (6.1%) and CYP2C19 poor metabolizers (1.7%), were identified.
  • Approximately 31% were CYP2D6 intermediate-poor metabolizers, and 48% carried hyperinducible CYP1A2*1F variants.

Findings:

  • No significant correlation was observed between CYP2D6 metabolizer status and the cause of death (drug toxicity, natural disease, external injury).
  • Multiple drug combinations were noted, suggesting potential pharmacokinetic or pharmacodynamic interactions.
  • The study did not find an over-representation of individuals with genetic predispositions to altered drug metabolism in drug toxicity cases compared to other causes.

Implications:

  • Genetic variability in drug metabolism does not appear to be a primary distinguishing factor for drug toxicity deaths in this Australian cohort.
  • Forensic toxicology should consider the prevalence of various CYP450 genotypes and potential drug-drug interactions.
  • Further research may explore other genetic or environmental factors contributing to drug toxicity in deceased populations.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...